RAP's track record is all due to incompetent leadership and management. That's what has failed Dr Abeyratne's research and inventions and the company's investors. In the right hands, this could have come to fruition by now and still can. That's why Pfizer wants it.
RAP Price at posting:
18.5¢ Sentiment: Hold Disclosure: Held
